FDA grants orphan-drug designation for TauRx’s LMTX in frontotemporal dementia
FDA grants orphan-drug designation for TauRx’s LMTX in frontotemporal dementia
ABERDEEN, Scotland and Singapore, 10th December, 2018 – TauRx, a leader in neurodegenerative disease research, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LMTX® for the
"treatment of frontotemporal dementia". The term Frontotemporal Dementia (FTD) covers a number of sub-types of dementia, all of which are characterized by a progressive loss of neurons in the frontal and/or temporal lobes of the brain.
Read more here.
FDA grants orphan-drug designation for LMTX
TauRx, a leader in neurodegenerative disease research, today announced that the US Food and Drug Administration (FDA) has granted orphan-drug designation for
Recent News
TauRx is attending Alzheimer’s Association International Conference in San Diego, USA, from 31 July to 4 August.
Jul 20, 2022
A few weeks ago, TauRx attended the 35th Alzheimer Disease International Conference held at the Oval in London.
Jun 22, 2022
Initial Data of LUCIDITY Study
May 31, 2022
Sonya Miller follows the science. In 2017, she followed it so completely and with such focus into a crowded conference room that she accidentally sat next to the CEO of TauRx Pharmaceuticals and talked herself into a job.
May 25, 2022